L Steven Zukerman, MD
Cardiovascular Disease · Eatontown, NJNPI 1326015306
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,614 of the $41,266 with a category attached, or 88.7%. E.r. Squibb & Sons, L.L.C. accounts for 82.4% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $11,735 and has fallen 98.0% since, to $229 in 2025. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 200 payments — averaging $206.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$34K
- Pfizer$6K
- Boston Scientific$570
- Impulse Dynamics (USA) Inc.$156
- Abbott$65
- Novartis$59
- plus $195 from 8 others
Across 55 payments — averaging $3488.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$183K
- Boehringer Ingelheim$7K
- Abbott$2K
What the payments were for
- Consulting fees$1,5004%
- Speaking & faculty fees$36,61489%
- Food & beverage$3,1448%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 104 | $33,994 |
| Pfizer | 72 | $6,226 |
| Boston Scientific | 7 | $570 |
| Impulse Dynamics (USA) Inc. | 2 | $156 |
| Abbott | 2 | $65 |
| Novartis | 4 | $59 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $45 |
| Heartflow, Inc. | 2 | $38 |
| Medtronic | 1 | $37 |
| Amgen | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,266 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,454 | $1,483,488 |
| MultaqDronedarone Hcl | 79 | $116,022 |
| XareltoRivaroxaban | 101 | $115,681 |
| Repatha SureclickEvolocumab | 100 | $87,146 |
| EntrestoSacubitril/Valsartan | 57 | $72,803 |
| Propafenone Hcl ErPropafenone Hcl | 140 | $29,668 |
| Nebivolol Hcl | 377 | $22,287 |
| Valsartan | 634 | $19,500 |
| FarxigaDapagliflozin Propanediol | 15 | $16,228 |
| LivaloPitavastatin Calcium | 21 | $15,691 |
| Rosuvastatin Calcium | 954 | $15,541 |
| Praluent PenAlirocumab | 20 | $13,566 |
| Metoprolol Succinate | 777 | $13,171 |
| BrilintaTicagrelor | 21 | $12,379 |
| JardianceEmpagliflozin | 14 | $11,596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $6,226 | $1,483,4881,454 claims |
| Johnson & JohnsonXarelto | $13 | $115,681101 claims |
| NovartisEntresto, Diovan | $59 | $77,27370 claims |
| Boehringer IngelheimJardiance | $17 | $11,59614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Eatontown
- Scott EisenbergEatontown$132K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.